164 related articles for article (PubMed ID: 34327872)
1. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial.
Okamura Y; Boku N; Ghaneh P; Greenhalf W; Yasukawa S; Narimatsu H; Fukutomi A; Konishi M; Morinaga S; Toyama H; Maeda A; Shimizu Y; Nakamori S; Sata N; Yamakita K; Takahashi A; Takayama W; Yamaguchi R; Tomikawa M; Yanagisawa A; Neoptolemos JP; Uesaka K
Cancer Rep (Hoboken); 2022 May; 5(5):e1507. PubMed ID: 34327872
[TBL] [Abstract][Full Text] [Related]
2. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.
Svrcek M; Cros J; Maréchal R; Bachet JB; Fléjou JF; Demetter P
Histopathology; 2015 Feb; 66(3):457-62. PubMed ID: 25298108
[TBL] [Abstract][Full Text] [Related]
3. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
[TBL] [Abstract][Full Text] [Related]
4. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Ormanns S; Heinemann V; Raponi M; Isaacson J; Laubender RP; Haas M; Kruger S; Kleespies A; Mann E; Bartosiewicz M; Kirchner T; Boeck S
Eur J Cancer; 2014 Jul; 50(11):1891-9. PubMed ID: 24857044
[TBL] [Abstract][Full Text] [Related]
5. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.
Okamura Y; Yasukawa S; Narimatsu H; Boku N; Fukutomi A; Konishi M; Morinaga S; Toyama H; Kaneoka Y; Shimizu Y; Nakamori S; Sata N; Yamakita K; Takahashi A; Kainuma O; Hishinuma S; Yamaguchi R; Nagino M; Hirano S; Yanagisawa A; Mori K; Uesaka K
Cancer Sci; 2020 Feb; 111(2):548-560. PubMed ID: 31778273
[TBL] [Abstract][Full Text] [Related]
6. A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine.
Kalloger SE; Riazy M; Tessier-Cloutier B; Karasinska JM; Gao D; Peixoto RD; Samimi S; Chow C; Wong HL; Mackey JR; Renouf DJ; Schaeffer DF
J Pathol Clin Res; 2017 Jul; 3(3):179-190. PubMed ID: 28770102
[TBL] [Abstract][Full Text] [Related]
7. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Farrell JJ; Elsaleh H; Garcia M; Lai R; Ammar A; Regine WF; Abrams R; Benson AB; Macdonald J; Cass CE; Dicker AP; Mackey JR
Gastroenterology; 2009 Jan; 136(1):187-95. PubMed ID: 18992248
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study.
Boyd LNC; Nooijen LE; Ali M; Puik JR; Moustaquim J; Fraga Rodrigues SM; Broos R; Belkouz A; Meijer LL; Le Large TYS; Erdmann JI; Hooijer GKJ; Heger M; Van Laarhoven HWM; Roos E; Kazemier G; Giovannetti E; Verheij J; Klümpen HJ
Front Pharmacol; 2023; 14():1274692. PubMed ID: 37920204
[No Abstract] [Full Text] [Related]
9. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
[TBL] [Abstract][Full Text] [Related]
10. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
11. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status.
Raffenne J; Nicolle R; Puleo F; Le Corre D; Boyez C; Marechal R; Emile JF; Demetter P; Bardier A; Laurent-Puig P; de Mestier L; Paradis V; Couvelard A; VanLathem JL; MacKey JR; Bachet JB; Svrcek M; Cros J
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31752123
[TBL] [Abstract][Full Text] [Related]
12. Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer.
Xiao JC; Zhang TP; Zhao YP
Hepatogastroenterology; 2013; 60(122):258-62. PubMed ID: 23574652
[TBL] [Abstract][Full Text] [Related]
13. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
Zhu Y; Qi M; Lao L; Wang W; Hua L; Bai G
Genet Test Mol Biomarkers; 2014 May; 18(5):306-12. PubMed ID: 24625353
[TBL] [Abstract][Full Text] [Related]
14. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
[TBL] [Abstract][Full Text] [Related]
15. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Greenhalf W; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Lamb RF; Garner E; Campbell F; Mackey JR; Costello E; Moore MJ; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Halloran CM; Mayerle J; Oláh A; Jackson R; Rawcliffe CL; Scarpa A; Bassi C; Büchler MW;
J Natl Cancer Inst; 2014 Jan; 106(1):djt347. PubMed ID: 24301456
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
Bird NT; Elmasry M; Jones R; Psarelli E; Dodd J; Malik H; Greenhalf W; Kitteringham N; Ghaneh P; Neoptolemos JP; Palmer D
Br J Surg; 2017 Mar; 104(4):328-336. PubMed ID: 28199010
[TBL] [Abstract][Full Text] [Related]
18. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.
Eto K; Kawakami H; Kuwatani M; Kudo T; Abe Y; Kawahata S; Takasawa A; Fukuoka M; Matsuno Y; Asaka M; Sakamoto N
Br J Cancer; 2013 Apr; 108(7):1488-94. PubMed ID: 23492684
[TBL] [Abstract][Full Text] [Related]
19. Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-Analysis.
Vos LJ; Yusuf D; Lui A; Abdelaziz Z; Ghosh S; Spratlin JL; Mackey JR
JCO Precis Oncol; 2019 Dec; 3():1-22. PubMed ID: 35100740
[TBL] [Abstract][Full Text] [Related]
20. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]